FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

Certificates

FDA

Document

No Title 0.39 MB
Registration Date 28 Jan 2015
Share

Oncaspar®

(0)

Medicine Pharmaceuticals Product Number : 54482-301-01

Antineoplastic Agent

Drug Information

Generic
Asparginase
NDC Code
54482-301-01
Drug Class
Asparaginase
Therapeutic Class
Antineoplastic
Dosage form
Solution
Route of Administration
SUBCUTANEOUS
Therapeutic Area
1.leukemia

Nanomaterials

Manufacturer Asserted

Polymeric Nanoparticle

Nanoparticle /Nanopowder

Indication

First Line Acute Lymphoblastic Leukemia (ALL) Acute Lymphoblastic Leukemia and Hypersensitivity to Asparaginase

Benefit

Oncaspar, with the generic name pegaspargase, is a PEGylated-l-asparaginase approved by the FDA in 1994. Acute lymphoblastic leukemia and chronic myelogenous leukemia are treated with this agent. It can also be used as a replacement in patients with leukemia who display hypersensitivity to E. coli-derived l-asparaginase. Oncaspar is beneficial as it is only administered every 2 weeks, while the native compound, l-asparaginase, must be administered three times per week. The less frequent administration of Oncaspar is simply the result of a longer half-life due to PEGylation. Furthermore, Oncaspar demonstrates decreased hypersensitivity and considerable total cost savings for patients.